Edwards Lifesciences Debt Securities, Available-for-Sale, Unrealized Loss Position increased by 222.2% to $488.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 216.4%, from $154.40M to $488.50M. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Unrealized Loss Position shows a downward trend with a -44.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher values indicate greater sensitivity to market interest rate fluctuations and credit spread changes.
The total unrealized loss position for available-for-sale debt securities, reflecting the difference between amortized c...
Standard disclosure in the investment securities section of financial statements for banks.
other_debt_securities_available_for_sale_unrealized_loss_ab3ae9| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $382.00M | $582.70M | $1.63B | $1.67B | $1.62B | $1.63B | $1.47B | $1.29B | $1.17B | $974.80M | $878.90M | $634.30M | $437.80M | $298.60M | $222.60M | $154.40M | $125.60M | $101.70M | $151.60M | $488.50M |
| QoQ Change | — | +52.5% | +180.2% | +2.3% | -2.8% | +0.7% | -10.4% | -11.8% | -9.6% | -16.5% | -9.8% | -27.8% | -31.0% | -31.8% | -25.5% | -30.6% | -18.7% | -19.0% | +49.1% | +222.2% |
| YoY Change | — | — | — | — | +324.9% | +180.6% | -10.2% | -22.7% | -28.1% | -40.4% | -40.0% | -50.9% | -62.5% | -69.4% | -74.7% | -75.7% | -71.3% | -65.9% | -31.9% | +216.4% |